Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of UTTR1147A in ulcerative colitis or Crohn's disease
2017-004997-32Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efmarodocokin alfa in autoimmune colitis and Crohn's disease, sponsored by Roche. Primary endpoint: Occurrence and severity of adverse events. Started Sep 2018; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2017-004997-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004997-32.